Benzonase Endonuclease Market

Key data points: Market size in 2027 = $397 million and 2035 = $638 million, growth forecast = 5.8% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in benzonase endonuclease market to 2035 by type (5kU, 25kU, 50kU, 100kU, and >100kU), application (biological laboratory, university research room, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Benzonase Endonuclease Market The future of the global benzonase endonuclease market looks promising with opportunities in the biological laboratory and university research room markets. The global benzonase endonuclease market is expected to reach an estimated $638 million by 2035 from $397 million in 2027 with a CAGR of 5.8% from 2027 to 2035. The major drivers for this market are the increasing use in biopharmaceutical purification processes, the rising demand for DNA RNA degradation solutions, and the growing adoption in vaccine & cell therapy production. • Lucintel forecasts that, within the type category, 100kU is expected to witness the highest growth over the forecast period due to the bulk usage and cost efficiency of 100kU packs. • Within the application category, biological laboratory is expected to witness higher growth over the forecast period due to increased activity in nucleic acid research. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to improvement of research facilities in the biotech and pharmaceutical sectors in the APAC region. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Benzonase Endonuclease Market The use of benzonase in biomanufacturing is evolving to incorporate this enzyme in more steps throughout biomanufacturing processes. The increasing demand for the enzyme between 2025 and 2027 will be attributed to rising demands for larger viral-based therapeutics and tighter control of process and product impurities. Lucintel expects and supports this evolving trend of employing nucleases in biomanufacturing. Factors Driving Demand for Benzonase in Biomanufacturing: • Larger Scale Bioprocessing: In 2025, several companies engaged in the manufacture of cell and gene therapies, established the use of nucleases in larger scale processes to remove host cell DNA to below regulatory limits. This trend is expected to continue in the following years. • Viral Vector Manufacturing: In 2025-2027, several companies manufacturing adeno-associated viruses and lentiviruses expanded their manufacturing capacities. Benzonase was employed in the harvest and clarification steps of the processes to remove nucleic acids. • GMP Supply: In 2025, suppliers of benzonase also focused on the removal of animal origin components to provide a consistent product. • Automation and Closed Processing: From 2025 to 2027, biomanufacturers will automate the addition of nucleases, single-use bag Mixing, and real-time process monitoring, and eliminate the need for manual processing. During this timeframe, there will be continued focus on improving automation to minimize operator exposure and increase process consistency. The Biopharma industry continues to focus on improving process efficiency and effectiveness through continuous/intensified processing. • Application Diversification: Outside of biologics, 2025 outlooks suggest endonucleases will find use in plasmid DNA preparation and sample/vaccine processes through digestion at concentrations of 1 to 250 U/mL. Increased usage will mean an emphasis on a portion of the Biologics industry and reduced reliance on a single therapy. Growing use of Benzonase and similar products in the validated/regulated processes of biopharma/vaccine manufacturing will be the primary driver of the endonuclease market. Similarly to Benzonase, products with comparable features and benefits should experience similar market opportunities and performance. Recent Developments in the Benzonase Endonuclease Market Benzonase endonuclease market development is projected to 2025 and 2026 on account of rising stringency by biopharma companies on control of process impurities and expansion of viral vectors. Lucintel has incorporated a positive outlook for market growth for production of gene therapies and recombinant vaccines and proteins. With increasing market demands, suppliers have shifted their strategy from product sales to provision of complete process solutions, i.e. from product sales to process solutions. • Capacity Expansion: In 2025, strengthening of bioprocessing supply chain by Merck’s Life Science business continued, on the back of 2024 sales of €11.5 billion by the business unit. • Technology Launch: In 2025, Sartorius announced an enhancement of its process solutions for removal of nucleic acids. • Strategic Partnerships: In 2025, increasing collaborations was observed among biopharma companies for contract manufacturing of viral vectors and plasmid DNAs. • Regulatory Approval: In 2025, the FDA granted approval to 10 novel therapies. As a result, drug manufacturers further intensified efforts to provide evidence on the removal of process impurities and validation of process controls. (December 2025) The annual transformations in the drug manufacturing industry brought about by approvals created a continued demand for consistent grades of nucleases in the industry. • Production Scale-up: The Cell and Gene Therapy industry in 2025 moved toward larger single use systems and larger batch production, (October 2025) creating a demand for Benzonase in bulk and automated dosing. The major driver for adoption of Benzonase in cell and gene therapy is for the removal of host cell DNA for viral vector based therapies. The adoption is primarily to meet compliance requirements. Barring the entry of other products, suppliers of Benzonase are expected to retain their market position. Strategic Growth Opportunities in the Benzonase Endonuclease Market Benzonase Endonuclease has gained commercial importance in biomanufacturing with the recent development of higher viral titers and the use of complex viral vectors. Around 2024-2026, the interest in Benzonase Endonuclease will increase for the commercialization of biopharmaceuticals. According to Lucintel, the performance and the extent of regulatory documentation of Benzonase Endonuclease will impact the competitiveness of biopharmaceutical manufacturing. • Cell and Gene Therapy Manufacturing: The contract development and manufacturing organizations (CDMOs) that produce viral vectors will benefit from the use of Benzonase Endonuclease to remove host-cell DNA. In January 2025, the FDA approved 32 Cell and Gene Therapy products. With the growing number of products, the sponsors will increase commercial production from clinical batches, thus increasing the demand for Benzonase Endonuclease. • MRNA Manufacturing: The companies that produce the raw materials (plasmids) using mRNA technology to produce vaccine will benefit from the use of Benzonase Endonuclease to remove template DNA. In May 2025, the WHO selected 15 organizations for technology transfer for mRNA vaccine manufacturing. These organizations will require a reliable provider of Benzonase Endonuclease and other related services. • GMP Manufacturing: Benzonase Endonuclease, along with other raw materials and APIs, will be purchased based on the price and the level of documentation provided by the supplier (e.g. customer case studies and end-to-end traceability of the supply chain). In March 2025, Merck announced the establishment of 60 GMP facilities. • Increased Demand for Bioprocessing: As local vaccine and biologics capacities increase, more suppliers and distributors are able to source from those locations. The Biopharmaceutical industry in India was worth over $20 Billion in October 2025. Other regions, including Asia and Latin America, will significantly grow in the same capacity. • Optimization and After-sale Services: Service innovations to help customers optimize nuclease and other reagents, and to help with technology transfers to enhance nuclease and other reagent hold and/or DNA clear times, will continue to be widely used. Gene therapy is rapidly advancing, with 200+ programs in the U.S. under the investigational distinction in February 2025. Benzonase will continue to be used in research and academic laboratories, and its use in other laboratories will increase. Suppliers that have the right products and application support will increase their market share. This will mainly be in the areas of cell and gene therapy, mRNA and other therapeutic biologics. Continued focus on the price of Benzonase and other competitive products will be important; however, avoiding failure, obtaining regulatory approval, and reliably providing products will be the main factors affecting customers' buying decisions. Benzonase Endonuclease Market Drivers and Challenges Benzonase endonuclease market has been impacted by various factors such as advancements in technology, Changes in the regulations, and growth in the biopharmaceutical industry. There is consistent demand for nucleic acid removal in various pharmaceuticals and biologicals. Lucintel has taken into consideration the influence of factors such as customer service, operations and supply chain, and product development and has determined the above factors to be the key elements for the market. Though the above factors drive the market, there are several challenges including competitive market, high market price and long customer adoption process. The factors responsible for driving this market include • Rising Demand for Biopharmaceuticals: With increased development and manufacture of cell and gene therapies, as well as other vector-based and protein-based biopharmaceuticals, there is a need for effective methods to remove DNA and RNA from final products. • Process Improvement and Automation: Cell and gene therapies (especially using viral vectors and/or with a modular and adaptable nature) require advanced downstream processes. Endonucleases can assist in achieving this. It is estimated that by March 2025, more than 2,000 such therapies will be in development. Thus, the demand for nucleic acid processing and clearance technologies will increase. Viscosity and filter-related processing challenges in biomanufacturing will continue to be of primary focus; however, in the next few years, higher recovery and other process-related challenges will be of primary interest. It is anticipated that Benzonase and similar products will play a growing role in bioprocessing. • Process Intensification: Rapid progress in bioprocessing and the deployment of high-density and continuous cell culture systems will result in the concentration of nucleic acid-related impurities in the final biopharmaceutical product. As such, more stringent methods for clearance of process-related impurities will be required. From June 2025, several sponsor companies implemented intensive production processes and other related improvements. It is expected that this focus will result in the increased use of Benzonase and related products. • Quality and Process Control: Throughout 2025, comparability and process control remained of primary importance to regulatory agencies. It is expected that in the next several years, the need for process control and comparability of Benzonase-related products will increase. • New Product Development: Suppliers is positively impacting the market through the introduction of higher-activity formulations, recombinant products, improved buffers, and market-specific product offerings. In February 2026, some suppliers launched enhanced nuclease formulations to expand the upper limit of the processing temperature and pH. Some new products can be active at higher temperatures and over a wide range of pH. These products will allow end users to use nuclease in more stringent and automatable chromatography-based purification processes. Some Market challenges are: • High Product Costs and The Cost of Product Validation: The high cost of benchmarking and validating the performance of benzonase and other similar products creates an economic barrier to adoption, primarily for small laboratories and start-ups in the biotechnology sector. In April 2025, bioprocessing industry surveys indicated that qualification and validation activities account for more than 15% of total project costs for the development of complex biologics. During the next three to five years, beneficiaries of this service will be inclined to evaluate and compare the activities and dosages of other nucleases, and postpone purchase until the economic activity volume of the organization warrants the investment. • Manufacturing and Supply Challenges: Customers are exposed to supply chain risks due to the nature of the fermentation and purification processes, and the transport and storage of the product. In November 2025, many biopharmaceutical companies reported lead times of more than 12 weeks for critical process reagents. In the near term, customers will endeavor to have dual suppliers, and suppliers in their geographical region. • Process Complexities and Regulations: Benzonase's performance is dependent on several variables including buffer formulation and temperature, and there are challenges associated with impurity removal and downstream processor compatibility. As a result, transferring a benzonase process to a different site is difficult. In 2026, sponsor organizations reported that during comparability assessments, multiple purification adjustments and scale-ups of benzonase processes were required, and this made the assessments very time consuming and challenging. During the next several years, process-related complexities and challenges will likely impede the broad, routine adoption of benzonase by most biopharmaceutical manufacturers. The use of Benzonase is expected to rise due to the growth in biologics, vaccines and other cell and gene therapy products. Increased understanding and regulation in this area along with improved procedures and industry practices will boost the use of Benzonase. However, rising industry demands, coupled with technical and regulatory complexity and the cost of Benzonase will challenge small and medium biopharmaceutical companies. The use of Benzonase will be dictated by a company's ability to produce Benzonase in an efficient, effective and economical manner. Benzonase is expected to gain industry acceptance and enhance the purification of biopharmaceutical products List of Benzonase Endonuclease Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies benzonase endonuclease market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the benzonase endonuclease market companies profiled in this report include- • RayBiotech • TransGen Biotech • AbMole BioScience • GenScript • Shanghai Biyuntian Biotechnology Benzonase Endonuclease Market by Segment The study includes a forecast for the global benzonase endonuclease market by type, application, and region. Benzonase Endonuclease Market by Type [Value ($M) from 2019 to 2035]: • 5kU • 25kU • 50kU • 100kU • >100kU Benzonase Endonuclease Market by Application [Value ($M) from 2019 to 2035]: • Biological Laboratory • University Research Room • Others Benzonase Endonuclease Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Benzonase Endonuclease Market The expanding benzonase endonuclease market is due to investment in biopharmaceutical manufacturing, more stringent viral clearance, and the adoption of single-use bioprocessing. From 2025-2027, Lucintel expects the market will be driven by the increasing demand for plasmid DNA, viral vectors and vaccines, and other pharmaceutical biologics. Endonucleases are used for the digestion of host cell DNA in recombinant DNA processes and for other Downstream Processing activities. • United States: Investments in biomanufacturing and related regulations favor the adoption of nucleases. In January 2025, the FDA announced that it had approved 300 biologics. Host cell DNA digestion endonucleases are among the reagents and products used for process impurities. These will be demand products for the Digital Process Control of biologics. • China: Domestic and foreign companies are investing in China’s biomanufacturing. China’s National Medical Products Administration issued revised and updated regulations for the manufacturing and sale of pharmaceuticals and biologics. Chinese biomanufacturing of vaccines, cell therapies and other recombinant pharmaceuticals will increase the demand for nucleases and other associated process controls and services. • Germany: In February 2025, Merck announced additional investments in its Life Science business, which includes sites in Germany. More broadly, investments to strengthen centralized European Life Science manufacturing should be beneficial to the Life Sciences industry and further facilitate the supply of benzonase, Benzonase®, for regulated manufacturing. • India: India’s 2025 budget increased funding to encourage growth in the pharmaceutical sector, including the manufacturing of vaccines. The budget increased the National Manufacturing Mission from 14,000 to 20,000 crore rupees, and should facilitate growth in the bio-pharmaceutical sector. India is poised to significantly enhance its production of vaccines and other pharmaceuticals, which in turn is likely to heighten demands for benzonase in upstream and downstream process steps. • Japan: New controls introduced by Japan’s Health Labor and Welfare Ministry in April 2025, will strengthen oversight of cell-based and other regenerative medicinal products. Likewise, an emphasis on advanced process control and aqueous processing in bio-pharmaceutical manufacturing may create an opportunity for the use of engineered, regulated endonucleases in cell-based therapies and other bio-pharmaceuticals. Features of the Global Benzonase Endonuclease Market Market Size Estimates: benzonase endonuclease market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: benzonase endonuclease market size by type, application, and region in terms of value ($B). Regional Analysis: benzonase endonuclease market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the benzonase endonuclease market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the benzonase endonuclease market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the benzonase endonuclease market by type (5ku, 25ku, 50ku, 100ku, and >100ku), application (biological laboratory, university research room, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?